UK Markets closed

Global $12.17 Billion Nuclear Medicine Markets to 2028: Beta-emitters, PET, SPECT, Alpha-emitters, Brachytherapy

·4-min read

Dublin, June 29, 2021 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global nuclear medicine market size is expected to reach USD 12.17 billion by 2028

The different types of nuclear medicine include diagnostic, therapeutic, and others. The diagnostic segment dominated the global radiopharmaceuticals market in 2020.

However, nuclear medicine is increasingly being used in therapeutic procedures for the treatment of cancer and thyroid-related conditions. Radioimmunotherapy uses radiation therapy, immunotherapy, and radiotracers for the treatment of certain types of cancer. Brachytherapy uses iridium-192, which is introduced in the body for the destruction of cancer cells.

The market is segmented into Beta-emitters, PET, SPECT, Alpha-emitters, brachytherapy, and others, based on modality. The SPECT (Single-photon emission computed tomography) segment dominated the global Radiopharmaceuticals market in 2020. SPECT scan is a nuclear imaging test that creates 3-D images using a radioactive substance and a special camera.

Some radioisotopes used for SPECT scans include fluorine-18, xenon-133, iodine-123, and thallium-201 among others. SPECT scan examines blood flow to organs and the functioning of internal organs. SPECT scans are mostly used for the diagnosis of heart diseases, brain abnormalities, and bone disorders in the market.

The different applications of nuclear medicine in the market include thyroid, cardiology, bone metastasis, oncology, neurology, gastroenterology, immunology, and others. Nuclear medicine is used in neurology to accurately detect Alzheimer's diseases, reveal brain abnormalities, and support surgical planning.

The need for high detection accuracy, improved detection speed, and enhanced patient experience has increased the adoption of nuclear medicine. Nuclear medicine enables doctors to diagnose diseases and tumors or recurrence, radiation planning, localization, and track treatment progress.

The hospital segment dominated the global radiopharmaceuticals market in 2020. The growing need for early detection of severe ailments, growing geriatric population, and rising healthcare expenditure in developing countries, such as India, China, and Japan, boost the adoption of nuclear medicine in hospitals.

North America dominated the global radiopharmaceuticals market in 2020 and is expected to maintain its dominance over the forecast period. Rising occurrence of chronic diseases, advanced treatment options, early detection of severe medical conditions, and technological advancements are some factors boosting the adoption of nuclear medicine in the region.

Increasing applications in cancer detection and the presence of well-established healthcare infrastructure further increases the demand for Nuclear Medicine in North America. Asia-Pacific is expected to experience significant growth during the forecast period owing to the increasing geriatric population, rising spending on healthcare, and significant government investments aimed at providing improved healthcare services.

Key Topics Covered:

1. Chapter 1. Introduction
1.1. Report Description
1.2. Stakeholders

2. Chapter 2. Executive Summary
2.1. Market Highlights

3. Chapter 3. Research Methodology
3.1. Overview
3.2. Data Sources

4. Chapter 4. Nuclear Medicine Market Insights
4.1. Nuclear Medicine - Industry snapshot
4.2. Nuclear Medicine Market Dynamics
4.3. Porter's Five Forces Analysis
4.4. Nuclear Medicine Market PESTLE Analysis
4.5. Value Chain Analysis
4.6. Competitive Ranking Analysis, 2020

5. Chapter 5. Nuclear Medicine Market Assessment by Type
5.1. Introduction
5.2. Diagnostic
5.3. Therapeutic

6. Chapter 6. Nuclear Medicine Market Assessment by Modality
6.1. Introduction
6.2. Beta-emitters
6.3. PET
6.4. SPECT
6.5. Alpha-emitters
6.6. Brachytherapy

7. Chapter 7. Nuclear Medicine Market Assessment by Application
7.1. Introduction
7.2. Thyroid
7.3. Cardiology
7.4. Bone Metastasis
7.5. Oncology
7.6. Neurology
7.7. Gastroenterology
7.8. Immunology

8. Chapter 8. Nuclear Medicine Market Assessment by End-User
8.1. Introduction
8.2. Hospitals
8.3. Clinics and Diagnostic Centers
8.4. Research Institutes

9. Chapter 9. Nuclear Medicine Market Assessment by Geography
9.1. Introduction

10. Chapter 10. Competitive Landscape
10.1. Expansion and Product Launch Analysis
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Chapter 11. Company Profiles
11.1. Bracco Imaging S.P.A.
11.2. Lantheus Medical Imaging, Inc.
11.3. NTP Radioisotopes Soc, LTD
11.4. Eckert & Ziegler Group
11.5. Jubilant Pharma LLC
11.6. Australian Nuclear Science & Technology Organization
11.7. Cardinal Health
11.8. Isotopia Molecular Imaging Limited
11.9. Bayer AG
11.10. The Institute for Radioelements
11.11. Curium SAS
11.12. Advanced Accelerator Applications
11.13. Nordion, Inc.
11.14. Mallinckrodt
11.15. GE Healthcare

For more information about this report visit https://www.researchandmarkets.com/r/t9x7tk

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting